US experts endorse Moderna's first mRNA flu vaccine, paving the way for a new mRNA seasonal shotExecutive summary: A US expert panel issued a positive evaluation of Moderna's mRNA flu vaccine, recommending its approval for the upcoming season. If approved, it would be the first mRNA‑based flu vaccine, expanding Moderna's product portfolio and confirming the viability of mRNA technology for seasonal infectious diseases. Moderna, the US expert panel, the US Food and Drug Administration, patients and healthcare providers The FDA will review the submission, with a decision expected later in 2026; competitors may accelerate their own mRNA flu programs in response.A US expert panel issued a positive evaluation of Moderna's mRNA flu vaccine, recommending its approval for the upcoming season. The report highlights the potential of mRNA technology to be used beyond COVID‑19 vaccines. No competing expert opinions were cited in the provided sources. The decision will be closely watched by regulators, competitors and investors.Connected developmentsVespa ti amo: el objeto que ha marcado la vida moderna cumple 80 añosDoes Moderna Need to Start Making Money?Open the full case file on Beyond →
Social Pulse
AI estimate · not scraped